<SEC-DOCUMENT>0001140361-23-054514.txt : 20231122
<SEC-HEADER>0001140361-23-054514.hdr.sgml : 20231122
<ACCEPTANCE-DATETIME>20231122192722
ACCESSION NUMBER:		0001140361-23-054514
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20231030
FILED AS OF DATE:		20231122
DATE AS OF CHANGE:		20231122

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI Group Ltd.
		CENTRAL INDEX KEY:			0001958461

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231434783

	BUSINESS ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023
		BUSINESS PHONE:		81-3-6214-3600

	MAIL ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI USA, Inc.
		CENTRAL INDEX KEY:			0001973229

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231434782

	BUSINESS ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-284-0324

	MAIL ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-10-30</periodOfReport>

    <issuer>
        <issuerCik>0001124105</issuerCik>
        <issuerName>GYRE THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>GYRE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001958461</rptOwnerCik>
            <rptOwnerName>GNI Group Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>NIHONBASHI-HONCHO YS BLDG 3F</rptOwnerStreet1>
            <rptOwnerStreet2>2-2-2 NIHONBASHI-HONCHO, CHUO-KU</rptOwnerStreet2>
            <rptOwnerCity>TOKYO</rptOwnerCity>
            <rptOwnerState>M0</rptOwnerState>
            <rptOwnerZipCode>103-0023</rptOwnerZipCode>
            <rptOwnerStateDescription>JAPAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001973229</rptOwnerCik>
            <rptOwnerName>GNI USA, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>12730 HIGH BLUFF DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92130</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-10-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>63588119</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>64005887</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Remarks</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents the number of shares of common stock of the Issuer received by the Reporting Person in exchange for the shares of Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (&quot;CPI&quot;) and Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271, held by the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the &quot;Business Combination Agreement&quot;), by and among Catalyst Biosciences, Inc., a Delaware corporation,</footnote>
        <footnote id="F2">[cont'd from FN 1] GNI USA, Inc., a Delaware corporation (&quot;GNI USA&quot;), the Reporting Person, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and CPI. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China.</footnote>
        <footnote id="F3">These securities are held by GNI USA which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&quot;GNI Japan&quot;). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.</signatureName>
        <signatureDate>2023-11-22</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI USA, Inc.</signatureName>
        <signatureDate>2023-11-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
